Videos

Rapid Refresh

Understanding the Role of 20S Proteasome in Cancer Pathogenesis

07/23/2024

This animation explains the role of the 20S proteasome in regulating the cellular life cycle and the effects of disruptions in the ubiquitin proteasome system.

This animation explains the role...

07/23/2024

APP Institute Oncology

Videos

Advocacy to Reduce the Impact of Drug Shortages on Cancer Care

07/23/2024

Laura Bray , MBA;

Laura Bray, MBA, talks about her experience as a patient advocate with Angels of Change and the key drivers impacting drug shortages.

Laura Bray, MBA, talks about her...

07/23/2024

Journal of Clinical Pathways

Videos

Recent Advancements in the Non–Small Cell Lung Cancer Treatment Landscape

07/22/2024

Sandip Patel , MD;

Sandip Patel, MD, discusses the latest updates in the non–small cell lung cancer (NSCLC) treatment landscape.

Sandip Patel, MD, discusses the...

07/22/2024

Journal of Clinical Pathways

Conference Coverage

Sequencing Vemurafenib, Cobimetinib, and Atezolizumab for Patients With High-Risk Melanoma

07/22/2024

Paolo Ascierto, MD, discusses primary results from the phase 2 NEO-TIM trial which assessed the best sequencing of vemurafenib, cobimetinib, and atezolizumab among patients with high-risk melanoma.

Paolo Ascierto, MD, discusses...

07/22/2024

Oncology

Video

Cochairs Preview First APP Institute Inflammatory Bowel Disease

07/22/2024

Kimberly Orleck and Kim Kearns, APP Institute Inflammatory Bowel Disease cochairs, provide a quick preview of the exciting agenda for the inaugural two-day virtual event.

Kimberly Orleck and Kim Kearns,...

07/22/2024

APP Institute Inflammatory Bowel Disease

Conference Coverage

Sequencing Vemurafenib, Cobimetinib, and Atezolizumab for Patients With High-Risk Melanoma

07/19/2024

Paolo Ascierto, MD, discusses primary results from the phase 2 NEO-TIM trial which assessed the best sequencing of vemurafenib, cobimetinib, and atezolizumab among patients with high-risk melanoma.

Paolo Ascierto, MD, discusses...

07/19/2024

Oncology

Conference Coverage

Durvalumab as Standard-of-Care Consolidation Treatment for Patients With Limited-Stage Small-Cell Lung Cancer

07/19/2024

David Spigel, MD, discusses the results from phase 3 ADRIATIC trial, evaluating durvalumab with or without tremelimumab as consolidation treatment for patients with limited-stage small-cell lung cancer.

David Spigel, MD, discusses the...

07/19/2024

Oncology

Video

Jessica Allegretti, MD, on Recent Advances in Anti-Interleukin Therapies

07/19/2024

Dr Allegretti provides key take-home points from her presentation at the AIBD regional meeting on how anti-interleukin therapies work to treat both Crohn's disease and ulcerative colitis,

Dr Allegretti provides key...

07/19/2024

Advances in Inflammatory Bowel Disease Network

Sponsored Video

The WHS WOUNDSHARK 2024 INNOVATION AWARD: Therapeutic BREAKTHROUGH — Eluciderm’s SuperHealer™️ Journey

07/18/2024

Eluciderm, Inc. won the WHS WOUNDSHARK 2024 INNOVATION AWARD at the 2024 International Symposium for Advanced Wound Care (SAWC 2024) as recognition for the anticipated market impact of its groundbreaking ELU42, a first-of-its-kind, topically...

Eluciderm, Inc. won the WHS...

07/18/2024

Wound Care

Videos

Trends in Therapeutic Utilization Among Patients With CLL: Results From the Lymphoma Coalition’s 2022 Global Patient Survey Presented at ASCO 2024

07/18/2024

Steve Kalloger, MSc, discusses the results from the Lymphoma Coalition’s 2022 Global Patient Survey regarding therapeutic utilization trends among patients with chronic lymphocytic leukemia (CLL).

Steve Kalloger, MSc, discusses...

07/18/2024

Journal of Clinical Pathways